NKGen Biotech Shares Rise 8% After FDA Clears IND Application for SNK01

By Chris Wack

NKGen Biotech shares were up 8% to $3.25 after the company said the U.S. Food and Drug Administration has cleared its investigational new drug application for SNK01 natural killer cell therapy for treatment of moderate Alzheimer's disease.

The stock hit its 52-week low of $2.86 on Oct. 13, and is down 67% in the past 12 months.

SNK01 is an autologous, non-genetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression.

The company said this approved trial of 30 patients with moderate Alzheimer's will hopefully begin before the end of this year, and the first interim data is expected in early third quarter of 2024.

Write to Chris Wack at [e-mail]

(END) Dow Jones Newswires

10-24-23 1041ET